Over recent years, China has become a growing region for conducting clinical trials, particularly for Japanese pharmaceutical companies.
10am CST (China)
11am KST (Korea)
3pm CET (EU-Central)
With a growing aging population, an estimated 2.2 billion hospital visits per year, an expansive network of qualified hospitals and research sites, and a skilled talent pool of clinical trial project leaders, China is an appealing location for clinical studies. The Chinese government is also supportive of international partnerships and has introduced an improved regulatory environment for more efficient and accelerated research and new drug approvals.
In this webinar, we will discuss the Chinese clinical trial landscape and how sponsors can address and ease common difficulties in managing a study in China. Attendees will learn:
- The impact of recent regulatory reforms, including China's Human Genetic Resources Regulation (HGRAC)
- Best practices for operational oversight and governance
- Practical tips and solutions for developing an effective communications plan
- How to address escalations
Qing Liu, MPH, MBA
Director, Project Management, ICON
Qing Liu heads project management for ICON China. She joined ICON in 2016, and has 15 years of clinical research experience, working in global pharmaceutical companies and clinical research organisations. Her expertise includes global phase 1 to 4 clinical trials, with dedicated generic and oncology drug development experience in the Asia Pacific region and in the United States. Qing holds two Master Degrees of MPH from Peking University and an MBA from Asia Metropolitan University.
This program is intended for pharmaceutical and biotech professionals involved in:
- Project management
- Medical affairs
- Regulatory affairs
- Clinical development